Top

Published in:

01-03-2012 | Letter to the editors

HP-NAP new therapy for bladder cancer: numquam periculum sine periculo vincitur

Authors: Gaia Codolo, Matteo Fassan, Mario M. D’Elios, Marina de Bernard

Published in: Cancer Immunology, Immunotherapy | Issue 3/2012

Excerpt

The letter by Kountouras and colleagues refers to the recent paper by Codolo et al. [1], reporting that the neutrophil-activating protein (HP-NAP) produced by H. pylori inhibits the growth of bladder cancer in a mouse model. In the letter, the authors raise some concerns regarding the possible targeting HP-NAP as a therapeutic strategy due to its possible neuronal damaging effects. …

Codolo G et al (2011) HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother. doi:10.1007/s00262-011-1087-2

Li W et al (2009) Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Mult Scler 15(12):1411–1421PubMedCrossRef

Kountouras J et al (2010) Helicobacter pylori with or without its neutrophil-activating protein may be the common denominator associated with multiple sclerosis and neuromyelitis optica. Mult Scler 16(3):376–377PubMedCrossRef

Kountouras J et al (2006) Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology 66(6):938–940PubMedCrossRef

Kountouras J et al (2008) Guillain-Barré syndrome. Lancet Neurol 7(12):1080–1081PubMedCrossRef

van Doorn PA, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 7(10):939–950PubMedCrossRef

Kountouras J et al (2011) Helicobacter pylori infection may trigger Guillain-Barré syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis. J Neurol Sci 305(1–2):167–168PubMedCrossRef

Yuki N, Shahrizaila N (2011) How do we identify infectious agents that trigger Guillain-Barré syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis? J Neurol Sci 302(1–2):1–5PubMedCrossRef

Malfertheiner P et al (2008) Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135(3):787–795PubMedCrossRef

10.

Amedei A et al (2006) The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 116(4):1092–1101PubMedCrossRef

11.

Polenghi A et al (2007) The neutrophil-activating protein of Helicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo. J Immunol 178(3):1312–1320PubMed

12.

D’Elios MM et al (2009) Helicobacter pylori, asthma and allergy. FEMS Immunol Med Microbiol 56(1):1–8PubMedCrossRef

Title: HP-NAP new therapy for bladder cancer: numquam periculum sine periculo vincitur
Authors: Gaia Codolo
Matteo Fassan
Mario M. D’Elios
Marina de Bernard
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1145-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2012

Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions

Advances in cellular therapy: 6th international symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice

Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients

In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer